Scientific advisory & consulting

Specialty perspective grounded in evidence, practice, and professional leadership.

Dr. Wallace advises pharmaceutical and biotechnology organizations on medical, scientific, educational, and clinician-facing questions in allergy and immunology.

Current advisory work

Active scientific and medical advisory relationships.

ARS · Aquestive · Bryn · ALK-Abelló, Inc. · Kenvue

Her perspective draws on community practice, academic teaching, evidence synthesis, guideline development, professional-society leadership, and decades of communicating with clinicians.

01

Clinical relevance

Connect scientific evidence and product questions to the realities of allergy practice and patient care.

02

Medical education

Shape credible clinician-facing education, faculty programs, learning tools, and scientific communication.

03

Specialty context

Bring a long view of guidelines, professional organizations, emerging therapies, and changing practice needs.

Previous advisory & consulting

A sustained record across industry partners.

2023–2025

ARS, Bryn, Genentech, Grifols, Kaléo, and AbbVie

2019–2021

Sanofi, Kaléo, Mylan, ALK, Bryn, and Optinose

2016–2017

MEDA, Sanofi, Mylan, LifeReach, Kaléo, DVB, Allergan, and Medical Marketing Solutions

2013–2015

Mylan, MEDA, Sanofi, NeoHealth, and related product-specific advisory work

Historical activity—presented separately

Pharmaceutical speaker-bureau experience.

Promotional speaker-bureau work is historical and is intentionally distinguished from current and past advisory/consulting activity.

2019

Sanofi, Kaléo, Optinose, and ALK

2017

Mylan and Kaléo

2016

MEDA

2015

Mylan and MEDA

2014

Mylan/MEDA, Sunovion, and TEVA

2013

Mylan, Sunovion, and TEVA speaker training

Advisory inquiries

Bring clinical credibility and educational judgment to the table.

Discuss an advisory engagement